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ABSTRACT 
 
Background: Female sex is associated with thromboembolism related to atrial fibrillation (AF). Left atrial (LA) 
diameter independently predicted incident cardiovascular (CV) major events in the general population. In AF 
patients, LA enlargement is associated to AF occurrence and recurrence. No data have previously been 
reported on the relationship between LA enlargement, sex and CV death in AF patients. 
Methods and Results: All patients enrolled in the AFFIRM Trial with available data about LA dimension were 
included in this post-hoc analysis. 
Of the 2,615 eligible for the present analysis, LA enlargement was recorded in 67.0%, more commonly in 
women than in men (p=0.032). Patients with LA enlargement had higher body mass index (BMI), and was 
more frequently hypertensive, diabetic, diagnosed with a structural heart disease, prior coronary artery disease 
(CAD) and heart failure (HF).  BMI, left ventricular mass, female sex and mitral valve insufficiency (p<0.001) 
were associated with LA enlargement. 
AF female patients with LA enlargement had a higher risk for CV death (p=0.011). LA diameter showed a 
significant association with CV death (p<0.001). Cox regression analysis demonstrated that LA diameter was 
an independent predictor of CV death in female AF patients (p=0.003).   
Conclusions: LA diameter enlargement is associated with female sex, and carries a higher risk for CV death, 
particularly in females. LA diameter was an independent predictor of CV death in female AF patients. 
 
Keywords: atrial fibrillation, women, left atrium, cardiovascular death.  
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1. INTRODUCTION 
Atrial fibrillation (AF) is the commonest cardiac rhythm disorder which is associated with an increased risk of 
adverse cardiovascular (CV) outcomes, including stroke, thromboembolism, heart failure and CV death[1].  
Worse clinical outcomes have been reported for female patients with AF compared to males[2]. 
Of note, female AF patients carry a higher risk of stroke and thromboembolism compared with males, 
independent of anticoagulant use[3].  Thus, female sex is included as a risk factor within the CHA2DS2-VASc 
score[4].  Independent of stroke risk, female patients with AF have higher mortality rates[5,6], even if the 
precise reasons accounting for this accentuated risk are poorly understood. 
 
Left atrium (LA) enlargement has been related to higher risk of developing AF[7] and adverse CV events[8–
10]. Beyond the impact on AF episode recurrences after ablation therapies[11,12], the clinical relevance of LA 
diameter, as assessed by trans-thoracic echocardiography, has been attributed to intracavitary thrombus 
formation given that LA enlargement is a surrogate marker of stroke risk[13].  
 
On the other hand, there are conflicting results for LA enlargement in predicting all-cause death and CV events 
in the general population, as well as in the high risk CV population[8–10,14,15]. These discordant findings may 
perhaps be due to the heterogeneity of studied populations and to the lack of standardization of 
echocardiographic measurements.  The influence of LA enlargement on CV death has been investigated in the 
general population showing an increased risk, particularly in males, even if this risk was mitigated by the 
influence of left ventricular mass (LVM)[16,17]. 
 
To the best of our knowledge, no data on LA enlargement, carefully defined according to properly 
echocardiographically-based sex-specific thresholds[18], and CV death have been described in AF, nor a 
relationship between sex and LA diameter in AF.  The aim of this study was to investigate the relationship 
between LA diameter and sex in an AF population and second, the influence of LA enlargement on CV death 
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risk related to sex.  To investigate these relationships, we performed a post-hoc analysis of the Atrial 
Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. 
 
2. METHODS 
The AFFIRM Trial was a prospective randomized trial investigating the difference of clinical outcomes between 
rate control versus rhythm control in the clinical management of patients with AF (ClinicalTrials.Gov Identifier: 
NCT00000556). United States National Heart, Lung, and Blood Institute (NHLBI) held study.  This post-hoc 
analysis is based on the original AFFIRM database, obtained from the National Institutes of Health.  The study 
protocol and the principal trial results have been described in detail elsewhere[19,20].  For the present 
analysis, all patients enrolled in the AFFIRM Trial which had available echocardiographic data about LA 
dimension were considered. According to the joint consensus statement between American Society of 
Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACI) for cardiac 
chambers quantification, LA enlargement was defined as a LA diameter greater than 3.8 cm in female 
patients, or >4.0 cm in male patients[18]. 
 
Thromboembolic risk was defined according to the CHA2DS2-VASc risk score[4]. ‘Low risk’ patients were 
defined as those males with a CHA2DS2-VASc score=0 or females with a CHA2DS2-VASc = 1; ‘moderate risk’ 
was defined as male patients with a CHA2DS2-VASc score = 1; ‘high risk’ was defined as patients with a 
CHA2DS2-VASc score ≥2[21]. 
 
2.1 Statistical Analyses 
All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with normal distribution 
were expressed as means and standard deviations, and tested for differences with the Student t test. Non-
normal variables were expressed as median and interquartile range (IQR) and differences tested with the 
Mann-Whitney U test. Categorical variables, expressed as counts and percentages, were analysed by a chi-
square test. 
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A regression analysis was performed in order to establish all clinical factors significantly associated with LA 
enlargement. All variables that were significantly different between the two groups at the baseline underwent a 
univariate analysis and those univariate predictors with a statistical significance of less than 10% were inserted 
into a forward multivariate logistic model.  Similarly, a regression analysis was performed with the 
echocardiographic indexes. Next, a complete multivariable regression analysis with all variables considered in 
the two previous models was performed. 
 
Kaplan-Meier (KM) curves for the occurrence of CV death, for overall population and stratified per male/female 
sex, according to LA enlargement and differences in survival distributors between subgroups was analysed 
using the Log-rank test.  To establish clinical factors consistently associated with CV death a Cox proportional 
hazards analysis was performed according to sex. LA diameter, considered as a continuous variable, and all 
clinical variables significantly different between the two groups underwent a univariate analysis, and all 
variables associated to CV death with a p level <0.10 were inserted in the forward stepwise multivariate model.  
A two-sided p value <0.05 was considered as statistically significant. All analyses were performed using SPSS 
v. 22.0 (IBM, NY, USA). 
 
3. RESULTS 
Of the total study population of 4,060 patients originally enrolled in the AFFIRM trial, echocardiographic data 
about LA diameter were available for 2,615 patients (64.4%). From the overall cohort 1,048 (40.1%) patients 
were females and median [IQR] age was 71 [65-76] years old. Median [IQR] value for LA diameter was 4.3 cm 
[3.9-4.8 cm]. Of the whole cohort, 71.6% (n=1,872) were diagnosed with hypertension, whilst a previous 
history of coronary artery disease (CAD) was reported in 35.4% (n=927). Significant valvular disease was 
recorded for 331 (12.7%) patients, while a history of dilated non-ischemic cardiomyopathy was reported in 
8.9% (n=234). High thromboembolic risk was recorded for 84.0% (n=2,196). 
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LA enlargement was recorded for the 67.0% (n=1,751), more frequently in females than in males (p=0.032) 
[Figure 1].  Demographic and clinical characteristics according to the presence or absence of a LA 
enlargement are reported in Table 1. Patients with LA enlargement were more commonly female (p=0.032) 
and with a higher body mass index (BMI) (p<0.001). Both hypertension and diabetes mellitus were more 
frequently reported in patients with LA enlargement compared to patients with normal LA diameter (p<0.001 
and p=0.005, respectively).  Prior myocardial infarction (MI) and CAD diagnosis were more common with LA 
enlargement (p=0.002), as well as heart failure (HF) p (p<0.001). Structural cardiac diseases, e.g. dilated non-
ischemic cardiomyopathy and valvular disease, were more common in patients with LA enlargement 
(p<0.001). Patients with LA enlargement were at higher thromboembolic risk compared to patients with normal 
LA diameter (p=0.001).  Patients with LA enlargement were more commonly treated with warfarin than patients 
with normal LA diameter (p<0.001). 
 
Echocardiographic indexes are summarised in Table 2.   Patients with LA enlargement had various functional 
and structural alterations in echocardiographic parameters, such as greater left ventricular mass (LVM), 
impaired left ventricular ejection fraction (LVEF) and mitral valve insufficiency (p<0.001). No difference was 
found in relative wall thickness (RWT), both defined as continuous or categorical variables. 
 
Logistic regression analysis (Table 3) for the presence of LA enlargement showed BMI (p<0.001), female sex 
(p=0.022), hypertension (p=0.034), HF (p=0.001), dilated non-ischemic cardiomyopathy (p=0.040) and valvular 
disease (p=0.008) to be significantly associated with LA enlargement. Among echocardiographic indexes, a 
multivariate logistic analysis when performed with LVM, mitral valve thickening, mitral valve insufficiency and 
annular calcification, found that all these variables were significant associated with LA enlargement (p<0.001 
and p=0.002, respectively). The final logistic model including all significant variables on univariate analysis 
found BMI, LVM, female sex and mitral valve insufficiency (p<0.001) to be significantly associated with LA 
enlargement. 
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Over a mean (SD) of follow-up of 3.5±1.3, there were a total of 210 CV death events. The incidence of CV 
death events was higher in patients with LA enlargement compared to patients with normal LA diameter, i.e. 
2.6% patient-years vs. 1.6% patient-years, respectively. 
 
Survival analysis shows that patients with LA enlargement were at higher risk of CV death (Log-Rank: 9.755, 
p=0.002). When performing survival analysis stratified according to sex, while difference in survival for male 
patients [Figure 2, Panel A] showed only a non-significant trend (Log-Rank: 3.455, p=0.063), female AF 
patients with LA enlargement [Figure 2, Panel B] had a significantly higher risk for CV death (Log-Rank: 6.546, 
p=0.011), compared to normal LA diameter. 
 
LA diameter, as a continuous variable, showed a significant association with CV death (unadjusted hazard 
ratio [HR]: 1.52, 95% confidence interval [CI]: 1.22-1.89, p<0.001).  A multivariable Cox regression analysis 
(Table 4) performed according to sex, shows that in male patients only HF and MI were independently 
associated to CV death (p<0.001).  Conversely in female patients, BMI (p=0.001), diabetes mellitus (p<0.001), 
HF (p=0.001) and LA diameter (p=0.003) were independently associated with CV death.  
 
The association between LA diameter and CV death in AF females was not mitigated when the Cox analysis 
was adjusted by warfarin use, aspirin concomitant therapy, LVM, left ventricular remodelling or any mitral valve 
abnormalities. 
 
4. DISCUSSION 
In the present study, LA enlargement as defined according to echocardiographically-based sex-specific 
thresholds, was more prevalent in AF women than men.  Second, of the clinical and echocardiographic 
variables, female sex, BMI, LVM and mitral valve insufficiency are independently associated with LA 
enlargement. Finally, LA enlargement was an independent predictor of CV death in AF women, after 
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adjustment for confounders.  Of note, the increased risk of CV death associated with LA enlargement was not 
influenced by LVM or mitral valve abnormalities, or by current antithrombotic therapy.  
 
Overall, these findings emphasize the role of LA size in the prognosis assessment of AF patients, beyond AF 
risk of recurrence and/or stroke, and underscore the clinical relevance of LA measurement to predict CV 
death, particularly in female AF patients. 
 
Many conditions are associated with LA remodelling and dilatation. LA enlargement is often the result of 
pressure and/or volume overload[22]. Indeed, LA enlargement due to pressure overload is usually secondary 
to increased LA afterload in the presence of mitral stenosis or LV dysfunction. LA volume overload can also 
result from mitral valve regurgitation. These LA chamber changes in cardiac hemodynamic are common in AF 
patients due to the high prevalence of comorbidities, such as hypertension, HF and CAD[23].  
 
In the AFFIRM cohort, which included both valvular and non-valvular AF patients[19], a high prevalence of LA 
enlargement can be a reliable expression of multiple concomitant CV conditions, such as hypertension or HF. 
Among the various clinical variables, only BMI and female sex were independently associated with LA 
enlargement. Indeed, body size and sex are traditionally considered as determinants of LA size[24]. In healthy 
subjects, the impact of sex on LA size can partially be accounted for by differences in body size between 
males and females, given that females have smaller LA size that persists even after normalization for body 
size[25]. Interestingly, when a sex-specific assessment of LA size is performed in AF patients, LA enlargement 
is more prevalent in females.  
 
Reasons for the higher prevalence of LA enlargement in AF women are uncertain. The higher frequency of 
clinical comorbidities such as hypertension, HF and left ventricular hypertrophy (LVH) favouring LA dilatation 
may only partially explain the higher LA enlargement in women. Nevertheless, we cannot exclude a sex 
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difference in atrial structural remodelling in AF patients perhaps related to more pronounced inflammatory 
milieu and abnormal fibrosis[26–29] in female atria, that may favour LA enlargement. 
 
Among cardiac abnormalities commonly detected by echocardiography, mitral valve abnormalities and LVH, 
defined as indexed by body mass surface, are more common in AF patients. Beyond mitral valve insufficiency 
as a result of long-term diastolic dysfunction in AF patients, LVH is highly prevalent in non-valvular AF 
patients, especially in females[30]; moreover, the prognostic value of increased LVM in AF patients for all-
cause death has been reported[31].  
 
Nonetheless, data on the relationship between LA size, alone or combined with LV alterations, on both CV and 
all-cause death are controversial. It remains unclear whether LA size could improve prognostic evaluation 
independent of abnormal mitral filling pattern, increased ventricular stiffness or LVH or synergistically with 
these conditions. Also, LA diameter alone has been shown to independently predict all-cause[9] and CV death 
in the general population[17]. Moreover, LA enlargement predicts overall mortality in high-risk groups, for 
example, in dilated cardiomyopathy[32] or LV dysfunction[33], acute MI[34,35] or those undergoing valve 
replacement for aortic stenosis[36] and mitral regurgitation[37]. In all of these clinical scenarios, the influence 
of LA diameter on CV death was mitigated by LV mass[8], LVH[16] and diastolic function[38].  
 
In the AFFIRM cohort, a trend for poor survival was observed in AF men with LA enlargement comparing to 
the men without. On the contrary, this difference in survival was significant in female AF patients. Thus, the 
incremental value of LA diameter was independently associated with CV death only in females. 
 
As a controlled randomized clinical trial, the AFFIRM protocol allowed long-term follow-up and high quality 
data on several clinical variables.  Also, the cohort was heterogeneous for patients’ characteristics and study 
procedures were related to patients’ baseline characteristics, while on-going clinical management was at the 
investigators discretion, reflecting a “real-world” setting of the clinical of AF management, thus allowing 
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generalizability of our results.   On the contrary, limitations include the lack of data on LA volume and its 
impact on CV death, as well as lack of data on LA function or detailed electrophysiological mechanistic data. 
As our findings are based on a post-hoc analysis, they need to be confirmed in further studies specifically 
powered for the purpose. 
 
In conclusion, LA diameter enlargement was associated with female sex, and carries a higher risk for CV 
death, particularly in females. LA diameter was an independent predictor of CV death in female AF patients. 
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Table 1: Clinical and Demographic Characteristics According to Left Atrium Diameter 
 Normal LA Diameter 
n=864 
LA Enlargement 
n=1,751 
p 
Age, years median [IQR] 70 [65-76] 71 [64-76] 1.000 
SBP, mmHg median [IQR] 2,603 134 [120-150] 134 [120-150] 0.843 
DBP, mmHg median [IQR] 2,603 78 [70-85] 78 [70-85] 0.529 
BMI, kg/m2 median [IQR] 1,582 26.8 [23.9-29.9] 28.8 [25.1-32.9] <0.001 
Female Sex, n (%) 321 (37.2) 727 (41.5) 0.032 
AF Episode 2,522 
First, n (%) 
Recurrent, n (%) 
 
534 (64.2) 
298 (35.8) 
 
1,046 (61.9) 
644 (38.1) 
0.264 
Treatment Arm 
Rate Control, n (%) 
Rhythm Control, n (%) 
 
427 (49.4) 
437 (50.6) 
 
874 (49.9) 
877 (50.1) 
0.813 
Hypertension, n (%) 567 (65.6) 1,305 (74.5) <0.001 
Smoking Habit, n (%) 103 (11.9) 204 (11.7) 0.840 
Diabetes, n (%) 141 (16.3) 366 (20.9) 0.005 
Heart Failure, n (%) 118 (13.7) 487 (27.8) <0.001 
Coronary Artery Disease, n (%) 270 (31.2) 657 (37.5) 0.002 
Myocardial Infarction, n (%) 108 (12.5) 302 (17.2) 0.002 
Dilated Non-Ischemic Cardiomyopathy, n (%) 45 (5.2) 189 (10.8) <0.001 
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Stroke/TIA, n (%) 111 (12.8) 227 (13.0) 0.933 
Prior Cardiac Interventional Procedures 66 (7.6) 134 (7.7) 0.990 
Valvular Disease, n (%) 75 (8.7) 256 (14.6) <0.001 
Peripheral Vascular Disease, n (%) 48 (5.6) 112 (6.4) 0.399 
Pulmonary Disease, n (%) 104 (12.0) 227 (13.0) 0.502 
Predominant Cardiac Disease 
None, (%) 
Coronary Artery Disease, n (%) 
Dilated Non-Ischemic Cardiomyopathy 
Hypertension, (%) 
Other, n (%) 
 
154 (17.8) 
171 (19.8) 
25 (2.9) 
472 (54.6) 
42 (4.9) 
 
164 (9.4) 
425 (24.3) 
112 (6.4) 
927 (52.9) 
123 (7.0) 
<0.001 
CHA2DS2-VASc, median [IQR] 3 [2-4] 3 [2-4] <0.001 
CHA2DS2-VASc Risk Category 
Low, n (%) 
Intermediate, n (%) 
High, n (%) 
 
9 (1.0) 
161 (18.6) 
694 (80.3) 
 
22 (1.3) 
227 (13.0) 
1,502 (85.8) 
0.001 
Pharmacological Treatments    
Aspirin, n (%) 234 (27.1) 428 (24.4) 0.144 
Warfarin, n (%) 688 (79.6) 1,554 (88.7) <0.001 
ARB/ACE inhibitor, n (%) 281 (32.5) 746 (42.6) <0.001 
Beta-blockers, n (%) 320 (37.0) 782 (44.7) <0.001 
Digoxin, n (%) 438 (50.7) 926 (52.9) 0.285 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 16 
Diltiazem, n (%) 264 (30.6) 532 (30.4) 0.935 
Verapamil, n (%) 86 (10.0) 167 (9.5) 0.738 
Legend: AF= atrial fibrillation; ACE= angiotensin converting enzyme; ARB= angiotensin II receptor blockers; 
BMI= body mass index; DBP= diastolic blood pressure; IQR= interquartile range; LA= left atrium; SBP= 
systolic blood pressure; TIA= transient ischemic attack.
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Table 2: Echocardiographic Indexes According to Left Atrial Diameter 
 Normal LA Diameter 
n=864 
LA Enlargement 
n=1,751 
p 
LA Diameter, cm median [IQR] 3.6 [3.3-3.9] 4.6 [4.3-5.0] <0.001 
LVEF, % median [IQR] 789 60 [54-65] 55 [45-64] <0.001 
IVS, cm median [IQR] 2,159 1.1 [1.0-1.2] 1.1 [1.0-1.3] <0.001 
LVEDD, cm median [IQR] 2,290 4.8 [4.3-5.2] 5.1 [4.6-5.6] <0.001 
LVPWT, cm median [IQR] 2,140 1.0 [0.9-1.2] 1.1 [1.0-1.2] <0.001 
LVM, gr median [IQR] 2,050 185.98 [150.56-230.23] 213.08 [173.61-268.54] <0.001 
RWT, median [IQR] 2,087 0.43 [0.38-0.50] 0.42 [0.37-0.49] 0.070 
RWT>0.42, n (%) 394 (55.0) 711 (51.9) 0.169 
Mitral Valve Thickening, n (%) 109 (12.8) 245 (14.1) 0.376 
Mitral Valve Insufficiency, n (%) 99 (11.7) 433 (24.9) <0.001 
Mitral Annular Calcification, n (%) 117 (13.8) 346 (19.9) <0.001 
Legend: IQR= interquartile range; IVS= interventricular septum; LA= left atrial; LVEDD= left ventricular end 
diastolic dimension; LVEF= left ventricular ejection fraction; LVM= left ventricular mass; LVPWT= left 
ventricular posterior wall thickness.  
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Table 3: Logistic Regression Analysis for Left Atrial Enlargement 
 Multivariate Analysis 
OR 95% CI p 
Clinical Variables    
BMI (Continuous Variable) 1.07 1.04-1.09 <0.001 
Sex (Female vs. Male) 1.30 1.04-1.63 0.022 
Hypertension 1.29 1.02-1.65 0.034 
Heart Failure 1.67 1.22-2.27 0.001 
Dilated Non-Ischemic Cardiomyopathy 1.63 1.02-2.57 0.040 
Valvular Disease 1.64 1.14-2.36 0.008 
Echocardiographic Indexes    
LVM (Continuous Variable) 1.01 1.00-1.01 <0.001 
Mitral Valve Insufficiency 2.41 1.85-3.13 <0.001 
Mitral Annular Calcification 1.50 1.15-1.96 0.002 
Final Model    
BMI (Continuous Variable) 1.05 1.02-1.07 <0.001 
Sex (Female vs. Male) 1.73 1.32-2.28 <0.001 
LVM (Continuous Variable) 1.01 1.00-1.01 <0.001 
Mitral Valve Insufficiency 3.04 2.10-4.39 <0.001 
Legend: BMI= body mass index; CI= confidence interval; LVM= left ventricular mass; OR= odds ratio. 
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Table 4: Multivariable Cox Regression Analysis for Cardiovascular Death According to Sex 
 Multivariate Analysis 
HR 95% CI p 
Males    
Heart Failure 2.80 1.62-4.84 <0.001 
Myocardial Infarction 2.68 1.54-4.65 <0.001 
Females    
BMI (Continuous Variable) 0.90 0.84-0.96 0.001 
Diabetes 6.12 3.09-12.14 <0.001 
Heart Failure 2.99 1.59-5.63 0.001 
Left Atrial Diameter (Continuous Variable) 2.28 1.33-3.90 0.003 
Legend: BMI= body mass index; CI= confidence interval; HR= hazard ratio. 
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Figure Legends 
Figure 1: Left atrial enlargement according to sex 
Legend: LA= left atrium. 
Figure 2: Kaplan-Meier Curves for Cardiovascular Death According to Sex 
Legend: Solid Line= Left Atrium Enlargement, Dashed Line= Normal Left Atrium Diameter. 
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